PACAP38 induces migraine-like attacks in patients with migraine without aura

Brain

Volumn 132, Issue 1, 2009, Pages 16-25

  Schytz, Henrik Winther ^a   Birk, Steffen ^a   Wienecke, Troels ^a   Kruuse, Christina ^a   Olesen, Jes ^a   Ashina, Messoud ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cerebral vessels; Migraine without aura; PACAP38; Parasympathetic nervous system; Transcranial Doppler

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTERY DIAMETER; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CONTROLLED STUDY; CRYING; DOPPLER ECHOGRAPHY; FACE EDEMA; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; IMAGE QUALITY; INFUSION; MALE; MEAN ARTERIAL PRESSURE; MIDDLE CEREBRAL ARTERY; MIGRAINE; MIGRAINE AURA; PRIORITY JOURNAL; RATING SCALE; TEMPORAL ARTERY; VASODILATATION;

EID: 58849084087     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn307     Document Type: Article

References (56)

1. Arimura A, Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front Neuroendocrinol 1995; 16: 53-88.
2. Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia 2006; 26: 1304-9.
3. Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, et al. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 2007; 140: 185-91.
4. Boni JL, Ploug KB, Olesen J, Jansen-Olesen I, Gupta S. The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. Cephalalgia 2008; in press.
5. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998; 79: 964-82.
6. Dahl A, Russell D, Nyberg-Hansen R, Rootwelt K. Effect of nitroglycerin on cerebral circulation measured by transcranial Doppler and SPECT. Stroke 1989; 20: 1733-6.
7. Dalsgaard T, Hannibal J, Fahrenkrug J, Larsen CR, Ottesen B. VIP and PACAP display different vasodilatory effects in rabbit coronary and cerebral arteries. Regul Pept 2003; 110: 179-88.
8. Davis-Taber R, Baker S, Lehto SG, Zhong C, Surowy CS, Faltynek CR, et al. Central Pituitary Adenylate Cyclase 1 Receptors Modulate Nociceptive Behaviors in Both Inflammatory and Neuropathic Pain States. J Pain 2008; 9: 449-56.
9. Dickson L, Aramori I, McCulloch J, Sharkey J, Finlayson K. A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology 2006; 51: 1086-98.
10. Dogrukol-Ak D, Tore F, Tuncel N. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr Pharm Des 2004; 10: 1325-40.
11. Edvinsson L, Owman C, Sjoberg NO. Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Res 1976; 115: 377-93.
12. Edvinsson L, Elsas T, Suzuki N, Shimizu T, Lee TJ. Origin and Co-localization of nitric oxide synthase, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microsc Res Tech 2001; 53: 221-8.
13. Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev 2005; 48: 438-56.
14. Fahrenkrug J, Hannibal J, Tams J, Georg B. Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab 2000; 20: 1205-14.
15. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 1991; 338: 13-17.
16. Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J, et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 2006; 26: 992-1003.
17. Hashimoto H, Shintani N, Baba A. New insights into the central PACAPergic system from the phenotypes in PACAP- and PACAP receptor-knockout mice. Ann N Y Acad Sci 2006; 1070: 75-89.
18. Hosoya M, Onda H, Ogi K, Masuda Y, Miyamoto Y, Ohtaki T, et al. Molecular cloning and functional expression of rat cDNAs encoding the receptor for pituitary adenylate cyclase activating polypeptide (PACAP). Biochem Biophys Res Commun 1993; 194: 133-43.
19. IHS. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004; 24 (Suppl.1): 9-160.
20. Ingram SL, Williams JT. Modulation of the hyperpolarization-activated current (Ih) by cyclic nucleotides in guinea-pig primary afferent neurons. J Physiol 1996; 492: 97-106.
21. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989; 38: 17-24.
22. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P. Arterial responses during migraine headache. Lancet 1990; 336: 837-9.
23. Jansen-Olesen I, Goadsby PJ, Uddman R, Edvinsson L. Vasoactive intestinal peptide (VIP) like peptides in the cerebral circulation of the cat. J Auton Nerv Syst 1994; 49: S97-103.
24. Jansen-Olesen I, Gulbenkian S, Engel U, Cunha e Sa M, Edvinsson L. Peptidergic and non-peptidergic innervation and vasomotor responses of human lenticulostriate and posterior cerebral arteries. Peptides 2004; 25: 2105-14.
25. Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 2003; 26: 696-705.
26. Knutsson M, Edvinsson L. Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport 2002; 13: 507-9.
27. Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003; 126: 241-7.
28. Kruuse C, Lassen LH, Iversen HK, Oestergaard S, Olesen J. Dipyridamole may induce migraine in patients with migraine without aura. Cephalalgia 2006; 26: 925-33.
29. Lassen LH, Thomsen LL, Olesen J. Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport 1995; 6: 1475-9.
30. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22: 54-61.
31. Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 2007; 130: 166-76.
32. Lutz EM, Sheward WJ,West KM,Morrow JA, Fink G, Harmar AJ. The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 1993; 334: 3-8.
33. Mabuchi T, Shintani N, Matsumura S, Okuda-Ashitaka E, Hashimoto H, Muratani T, et al. Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. J Neurosci 2004; 24: 7283-91.
34. Markwalder TM, Grolimund P, Seiler RW, Roth F, Aaslid R. Dependency of blood flow velocity in the middle cerebral artery on end-tidal carbon dioxide partial pressure - a transcranial ultrasound Doppler study. J Cereb Blood Flow Metab 1984; 4: 368-72.
35. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990; 300: 230-5.
36. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19: 115-27.
37. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164: 567-74.
38. Ohsawa M, Brailoiu GC, Shiraki M, Dun NJ, Paul K, Tseng LF. Modulation of nociceptive transmission by pituitary adenylate cyclase activating polypeptide in the spinal cord of the mouse. Pain 2002; 100: 27-34.
39. Olesen J, Goadsby PJ. Synthesis of migraine mechanisms. The Headaches. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 393-8.
40. Ottosson A, Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 1997; 17: 166-74.
41. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 2008; 28: 226-36.
42. Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, Pang X, Theoharides TC. Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo. Brain Res 1999; 849: 1-15.
43. Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is not associated with cerebral or meningeal vasodilatation - a 3T magnetic resonance angiography study. Brain 2008; 131: 2192-200.
44. Seki Y, Suzuki Y, Baskaya MK, Kano T, Saito K, Takayasu M, et al. The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs. Eur J Pharmacol 1995; 275: 259-66.
45. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996; 384: 560-4.
46. Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 1999; 76: 176-83.
47. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev 2005; 49: 65-76.
48. Thomsen LL, Iversen HK. Experimental and biological variation of three-dimensional transcranial Doppler measurements. J Appl Physiol 1993; 75: 2805-10.
49. Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor triggers genuine migraine attacks. Eur J Neurol 1994; 1: 73-80.
50. Thomsen LL, Ahlgren MG, Iversen HK, Olesen J. Middle cerebral artery blood flow velocity increases during experimental pressure pain in the head. Philadelphia: Lippencott-Raven Publishers; 1995. p. 337-9.
51. Uddman R, Goadsby PJ, Jansen I, Edvinsson L. PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. J Cereb Blood Flow Metab 1993; 13: 291-7.
52. Uddman R, Tajti J, Moller S, Sundler F, Edvinsson L. Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res 1999; 826: 193-9.
53. Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002; 22: 112-6.
54. Warren JB, Cockcroft JR, Larkin SW, Kajekar R, Macrae A, Ghatei MA, et al. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator in humans. J Cardiovasc Pharmacol 1992; 20: 83-7.
55. Welch KM. Contemporary concepts of migraine pathogenesis. Neurology 2003; 61: S2-8.
56. Zhang Y, Malmberg AB, Yaksh TL, Sjolund B, Sundler F, Hakanson R. Capsaicin-evoked release of pituitary adenylate cyclase activating peptide (PACAP) and calcitonin gene-related peptide (CGRP) from rat spinal cord in vivo. Regul Pept 1997; 69: 83-7.